Browse > Article
http://dx.doi.org/10.15429/jkomor.2019.19.1.79

Effects of Combination Therapy with Anti-Obesity Herbal Medicine Including Ephedra Herba and Lorcaserin in Obese Patients: Two Case Reports  

Kim, Min-Jee (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University)
Choi, Han Seok (Department of Endocrinology Medicine, College of Medicine, Dongguk University)
Kim, Hojun (Department of Rehabilitation Medicine of Korean Medicine, College of Korean Medicine, Dongguk University)
Publication Information
Journal of Korean Medicine for Obesity Research / v.19, no.1, 2019 , pp. 79-87 More about this Journal
Abstract
Although there has been many studies about the co-administration of herb formula and western medicine, there is none about obesity. The aim of this study was to report the effects of co-administration of herb formula containing ephedra sinica and lorcaserin on two obese patients for about 2~4 months. During the treatment, we checked body weight and body composition, and collected blood samples to evaluate liver, kidney, thyroid function and lipid profile. This treatment not only decreased body weight but also improved body composition and lipid profile in both patients. There was no hepatic or renal toxicity, nor any serious side effects of treatment. This study demonstrated that co-administration of herb formula containing ephedra sinica and lorcaserin is a safe and effective therapy to lose weight and improve metabolic parameters for obese patients. Further large-scale clinical trials are needed to evaluate the anti-obesity effect of the combination of herbal and western medicines.
Keywords
Obesity; Lorcaserin; Ephedra;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 KNHANES. Health behaviors and chronic disease statistics, 2016 [Internet]. Cheongju: Korea Centers for Disease Control and Prevention (KCDC); 2016 [cited 2019 May 18]. Available from: https://knhanes.cdc.go.kr/knhanes/sub04/sub04_03.do?classType=7.
2 Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019 ; 15(5) : 288-98.   DOI
3 Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, et al. Coadministration of Lorcaserin and Phentermine for weight management: A 12-week, randomized, pilot safety study. Obesity (Silver Spring). 2017 ; 25(5) : 857-65.   DOI
4 Jo GW, Ok JM, Kim SY, Lim YW. Review on the efficacy and safety of Mahuang and ephedrine in the treatment of obesity -Focused on RCT-. Korean J Med. 2017 ; 38(3) : 170-84.   DOI
5 Ogden CL, Yanovski SZ, Carroll MD, Flegal KM. The epidemiology of obesity. 2007 ; 132(6) : 2087-102.   DOI
6 Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea. J Obes Metab Syndr. 2019 ; 28(1) : 40-5.   DOI
7 Kim MK, Kim CS. Recent advances in anti-obesity agents. Korean J Med. 2018 ; 93(6) : 501-8.   DOI
8 Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000 ; 9(2) : 160-7.   DOI
9 Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014 ; 8 : 1419-27.
10 Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017 ; 3(1) : 3-14.   DOI
11 Brashier DB, Sharma AK, Dahiya N, Singh SK, Khadka A. Lorcaserin: A novel antiobesity drug. J Pharmacol Pharmacother. 2014 ; 5(2) : 175-8.   DOI
12 Bessesen DH, Van Gaal LF. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018 ; 6(3) : 237-48.   DOI
13 Cavaliere H, Floriano I, Medeiros-Neto G. Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid). Int J Obes Relat Metab Disord. 2001 ; 25(7) : 1095-9.   DOI
14 Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004 ; 34(13) : 871-89.   DOI
15 White LM, Gardner SF, Gurley BJ, Marx MA, Wang PL, Estes M. Pharmacokinetics and cardioVAScular effects of ma-huang (Ephedra sinica) in normotensive adults. J Clin Pharmacol. 1997 ; 37(2) : 116-22.   DOI
16 Shannon JR, Gottesdiener K, Jordan J, Chen K, Flattery S, Larson PJ, et al. Acute effect of ephedrine on 24-h energy balance. Clin Sci (Lond). 1999 ; 96(5) : 483-91.   DOI
17 Song YK, Lim HH. Clinical application of Ma Huang in the obesity treatment. J Korean Med Obes Res. 2007 ; 7(1) : 1-7.
18 Kim HJ, Han CH, Lee EJ, Song YK, Shin BC, Kim YK. A clinical practice guideline for Ma-huang (Ephedra sinica) prescription in obesity. J Korean Med Obes Res. 2007 ; 7(2) : 27-37.